ERIC BREWER: Open Payments
NPI 1275957912 · PENSACOLA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,013 in 105 payments from 20 companies in 2025. Trend: 2023 $1,248 · 2024 $1,774 · 2025 $2,013
Food & beverage: $1,968Education: $45
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $416 |
| Novo Nordisk Inc | 18 | $279 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $174 |
| AstraZeneca Pharmaceuticals LP | 5 | $163 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $145 |
| Phathom Pharmaceuticals, Inc. | 11 | $129 |
| Lilly USA, LLC | 7 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $97 |
| Abbott Laboratories | 1 | $84 |
| Astellas Pharma US Inc | 3 | $79 |
Products named: JARDIANCE, VRAYLAR, Ozempic, QULIPTA, XIFAXAN, VOQUEZNA, TRINTELLIX, BREZTRI.
Industry payments across FL — which companies pay providers there.
